Outside this study, a dramatic response to palbociclib has been reported in a 62‐year‐old patient with advanced refractory CDKN2A‐deficient chordoma who had been surgically treated for seven recurring tumors over the course of 20 years (manuscript under review, personal communication 23 March 2021 from Dr Mrinal Gounder, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, USA). Here, CDKN2A is linked to chordoma.